Subject Index, 1979
Vol. 29, Nos. 1-6

A

Adriamycin
For breast cancer, 324
For lung cancer, small cell, 274
And vitamin E, 283

Aging, and cancer (See also, specific sites)
And clinical trials, 337
Endocrinology in, 336
Epidemiology in, 335-336
And genetic diseases, 334-335
Immunology in, 337-338
Incidence of, 322-323, 325, 328, 333, 335-337
And management, 323-330, 335-338 (See also, specific treatment modalities)
Mortality rates of, 335-336, 353
And mutagenesis, 338-339
And National Institute on Aging (NIA), 339
Pathology of cellular aging, 334
And research, 333-338
Risk of cancer in the elderly, 322
And virus induced tumors, 334

Anorexia, in childhood cancer, 41

Antigens, tumor specific, 363-366
In ovarian cancer, 345

Atomic bomb, radiation and cancer, 309, 312-313

B

BCG Administration (See, Immunotherapy)

Biochemical assays
Of endocrine tumors, 35
Of functioning tumors, 130-131, 140

Biopsy (See also, Diagnosis, cancer)
Aspiration, 22
Conization, 177-180, 188-189
Of cervical cancer, 177-180, 188
Excisional, 23, 25
Frozen Section, 27-30, 36
In breast exams, 28
Reliability of, 30, 36
And tumor implantation, 28
Incisional, 23
And tumor implantation, 23, 28
Needle, 22-24
And tumor implantation, 23, 28, 131-132, 138
Techniques and applications, 22-25

Bladder cancer
Grading of, 66
And occupational carcinogens, 145
And pyridoxine, B_6, 282
And radiation exposure, 311-313
Use of retinoids in, 123-124, 281
Staging of, 67

Bone cancer
Osteogenic sarcoma
Pathologic grading of, 66
Secondary to lung cancer, 86
And radiation exposure, 311-313
Radiation therapy in, 138

Bowen's disease (See, Skin cancer)

Brain cancer
And radiation exposure, 311-313
Secondary to lung cancer (CNS), 86, 88, 268-270

Breast cancer
And Cancer Family Syndrome (CFS), 225
Classification of, 68-69
Clinical examination for, 47
In C_3H mice, 57-62
Cowden's disease, 221, 226
Diagnosis of, 28, 63-64
In the elderly, 322-325, 336
Heredo-familial breast cancer (See, Genetics, and cancer)
Incidence of, 58-61, 323
And lymphatic spread, 134
Mammography (See, Mammography)
Management of, 323-325
(See also, specific treatment modalities)
Mastectomy, prophylactic, 221-222, 226
Medullary breast cancer with liver cancer, ileal carcinoid and pulmonary aspergillosis (case report), 373-376
And pyridoxine, B_6, 282-283
And radiation exposure, 311-313
Screening for, 47-50, 63-66

C

Cancer, in patients with advanced disease (See also, Hospice approach)
Active therapy for, 108-109, 111
Other diseases in, 109
"Quality of survival" data for, 301-305

Carcinogens
Animal studies involving, 150-152, 154, 156-163
And bladder cancer, 145
Control measures for, 155, 163-164
In the elderly, 336, 338
Epidemiological methods for determining risks of, 146-153
Exposure to, 144-145, 154-163
Federally regulated agents, 154-164
History of, 145-146
Incidence of occupational cancers, 144, 163
In vitro studies of, 152, 154
Latency period of, 155-162
And mutagenic activity, 154
And radiation exposure, 160-162, 309-313
Risks of, 146-153, 155-163
Role of government in, 154-164
Route of absorption, 154-162
Target tissues and organs, 155-162
Threshold Limit Values of, 152, 155, 163

Cervical cancer
Classification of, 69-70, 181-186
Clinical trials of, 184-190
Detection and diagnosis of, 26, 70, 174-189
Carcinoma in situ, 186-187
Dysplasia, 181-185
In the elderly, 336-337
Microinvasive carcinoma, 189
Papanicolaou technique, 174-176, 344-345
Incidence of, 174-175, 187-188
And lymphatic spread, 134
Management of, 181-182, 185-186, 188-190
Carcinoma in situ, 188
Dysplasia, 185-186
Microinvasive carcinoma, 188-190
And pregnancy, 178, 181, 188
Staging of, 67

Chemoprevention, cancer, and retinoids, 120-125, 281

Chemotherapy, cancer
(See also, specific agents)
For breast cancer, 324
In childhood cancer, 40-42
For colon and rectum cancer, 329
In the elderly, 324, 326-330, 335
And enteral management, 82
For gastrointestinal cancer, 329
For leukemia, 326-327
For lung cancer, 84, 90-93, 243-244, 272-274, 328, 371-372
For melanoma, 206-209
For ovarian cancer, 341-342
For thyroid cancer, 323
And vitamins, interaction with, 280-285

Childhood cancer
Chemotherapy, effects on diet, 40, 42
Incidence of, 13
Mortality of, 13
Nutritional therapy in
(See, Nutritional therapy, for cancer)

Clinical Oncology Programs (COPs), 300-305

Clinical trials, cancer
Of cancer and aging, 337
Endometrial cancer and estrogens, 252-255
National Cancer Institute Cooperative Clinical Trials Program, 286-290
And retinoid therapy, 123-124

Colon and rectum cancer
And Cancer Family Syndrome (CFS), 225-226
Diagnosis of, 126-127, 220, 223
And dietary factors, 291-294
In the elderly, 336
And environmental factors, 291-292
And genetic factors, 218, 223-227, 292-297
(See also, Genetics, and cancer)
Familial Polyposis Coli (FPC), 218, 223-225
And Heredo-familial breast cancer, 222
Ileal carcinoid, medullary breast cancer and pulmonary aspergillosis with liver cancer (case report), 373-376
And radiation exposure, 311-313
And cancers of the reproductive system, 296
Staging of, 67
And tumor implantation of the large bowel, 132, 138-139
And vein invasion, 136-137

Colorectal polyps
Hereditary, 218-227, 295-296
(See also, Genetics, and cancer)
Management of, 223-225
(See also, specific treatment modalities)
As precancerous lesions, 127-128, 223-225, 229, 295-297
Prognosis of, 127-128
Screening for, 127-128, 223

Colposcopy, in cervical cancer, 70, 176-180, 337

Cowden's disease, 221, 226
(See also, Genetics, and cancer)

Cryotherapy, for cervical cancer, 185-186

Cyclophosphamide
For breast cancer, 324
For small cell lung cancer, 274

Cytology
For cervical cancer, 26, 174-176, 179-181, 189
For endometrial cancer, 26
For gastric cancer, 26-27
For general diagnosis, 25-29
For lung cancer, 25-26, 234
Stains, special, 33-37
For transitional cell carcinomas, 27

D

Diagnosis, cancer
Biochemical studies, 35, 130-131, 140
Biopsy techniques and applications, 22-25, 27-30, 36 (See also, Biopsy)
Of breast cancer, 63-64
Of cervical cancer, 177-189, 344-345
Of colon and rectum cancer, 126-127, 328
Cytology, 25-29, 33-37, 174-176, 179-181, 189, 234
(See also, Cytology)
In the elderly, 328, 336-337
Electron microscopy, 31, 34-35, 38-39, 88-89, 130-131, 140, 258
Of Familial Atypical Multiple Mole-Melanoma syndrome (FAMMM), 226, 228
Gross examinations, 30-31, 35
Immunocytochemical techniques, 33-34, 37, 130-131, 140

Of lung cancer, 88-89, 234-239, 258-259, 263-273
Of melanoma, 198-199
Microscopic examination, 31-33
Of ovarian cancer, 341, 344-347, 351
Of prostate cancer, 116-118
Tissue culture, 35

Diet, and cancer
(See, Colon and rectum cancer, and Nutritional therapy, for cancer)

E

Editorials, diagnosis of breast cancer, 63-64

Electrocoagulation, for cervical cancer, 185-186

Electron microscopy
Of functioning tumors, 130-131, 140
In lung cancer, 88-89, 258
Of lymph nodes, 31, 34-35, 38-39

Endocrinology, and cancer and aging, 336

Endometrial cancer
And Cancer Family Syndrome (CFS), 225
Cytologic diagnosis of, 26
In the elderly, 322
And replacement estrogens, 250-255, 336

Enteral management, of cancer patients
Candidates for, 78
And chemotherapy, 82
In children, 43
Defined formulas for, 80-83
Entry sites for tubes, 78-80
Route of feeding, 83

Environment and cancer
(See, Carcinogens)

Epidemiology
And aging and cancer, 335-336
American Cancer Society (ACS) cancer prevention study, 353, 356-357, 359
Cancer mortality in underdeveloped countries, 353
Classification of data, 2-5
For determining risks of occupational carcinogens, 146-153
Dorn U.S. Veterans study, 353-354, 356-357, 359
Low-risk mortality populations, 352-361
(See also, Low-risk cancer populations)

F

Fiberbronchoscopy, in diagnosis of lung cancer, 238

5-Fluorouracil
For breast cancer, 324
For gastrointestinal cancer, 329

Functioning tumors, diagnostic techniques for, 130-131, 140

G

Gallium 67 scan (GA-67), for lung cancer, 259, 262-273

Gardner's syndrome, 218, 223, 225, 295-297
(See also, Genetics, and cancer)

Gastric carcinoma
Cytologic diagnois of, 26-27
In the elderly, 322, 328-329, 336-337
And Heredo-familial breast cancer, 222
Management of, 328-329

Genetics, and cancer
And aging, 334-335
Breast cancer in C_3H mice, 57-60
Cancer Family Syndrome (CFS), 221, 225-226
Diagnostic criteria for, 225
Management of, 221, 226
(See also, specific treatment modalities)
Screening for, 221
In colon and rectum cancer, 225-226, 293-297
Cowden's disease, 221, 226
Familial Atypical Multiple Mole-Melanoma syndrome (FAMMM), 222-226, 228
Diagnosis of, 226, 228
Management of, 222, 228
Screening of, 222, 228
Transmission of, 228
Familial cancer registries, 217-218, 220-222
Familial multiple adenomatous polyposis coli, 218, 224-225
Familial Polyposis Coli (FPC), 218, 223-225, 295-297
Chronology of, 218, 224
Diagnosis of, 218, 223
Incidence of, 218, 296
Management of, 218, 223-225
Pathogenesis of, 218, 224
Screening for, 223-224
Family cancer, compilation of history, 217
Gardner's syndrome, 218, 223, 225, 295-297
Heredo-familial breast cancer, 216-217, 219, 221-222, 226
General characteristics, 216
Incidence of, 226
And other malignant neoplasms, 219, 222, 226
Management of, 221-222, 226
And SBLA syndrome, 222
Screening for, 216-217, 219, 221-222, 226
Transmission of, 219-226
Multiple endocrine adenomatosis (MEA), Types I, II, III, 220, 228-229
Oldfield syndrome, 296
Peutz-Jeghers syndrome, 296
And precancerous lesions, 223-225, 229
Turcot's syndrome (polyposis-glioma syndrome), 223, 296

Government, and cancer
Federally regulated carcinogens, 154-164
Federal safety standards for radiation exposure, 309
HEW's Second Opinion Program (letter), 172-173

H

Hemoccult test, for screening of colon and rectum cancer, 126-127

Hereditary factors, and cancer
(See, Genetics, and cancer)

Hodgkin's disease (See, Lymphomas)

Hormonal treatment, in cancer
For breast cancer, 324-326
In the elderly, 323-326
Estrogen and endometrial cancer, 250-255, 336
For prostate cancer, 325-326
Thymic hormone treatment, 364
For thyroid cancer, 323

Hospice approach, to terminal cancer
Candidates for (Opinion), 109-111
In Community Clinical Oncology Programs (COPs), 305
And patient participation (letter), 53

Hyperalimentation
Intravenous hyperalimentation (IVH) in childhood cancer, 40-41, 44
In ovarian cancer, 341-342

I

Immunocytochemical techniques, 33-34, 37, 130-131, 140
Use in diagnosing functioning tumors, 130-131, 140
Sternberger's technique, 34

Immunology
And cancer and aging, 337-338
Immunologic techniques in diagnosing ovarian cancer, 345

Immunotherapy
BCG vaccine, 363-364
For lung cancer (intrapleural), 243, 273
For melanoma, 209, 363
For ovarian cancer, 341
For thyroid cancer, 323
In combination with other treatment modalities, 363-364
Effectiveness of, 363-364, 367-369
In infectious diseases, 368-369
Nonspecific stimulation of immune response, 363-364
Present and future status of, 367-369
Thymic hormone treatment, 364
Tumor enhancement from, 368
Tumor-specific immunotherapy, 364-367
Active immunization, 365
Passive immunization, 365-367
Adoptive immunotherapy, 362, 366-367
Serotherapy, 365, 369

Informed concent, of patient, right or rite? (Opinion), 316-318

Interferon, 53, 363

K

Kidney cancer
And radiation exposure, 311-313
Secondary to lung cancer, 269-270
By vein invasion, 136-137

L

Laparoscopy, in ovarian cancer, 344-345

Laparotomy, in ovarian cancer, 344, 351

Leucovorin rescue, for small cell lung cancer, 274

Leukemia
ALL mimicking renal failure (case report), 319-320
In the elderly, 326-327, 336-337
And lymphomas, distinction between, 74
Management of, 326-327
And radiation exposure, 311-313
Survival rates for, 326
And vitamin B_{12}, 282

Leukoplakia, and vitamin A, as treatment, 280

Liver cancer
Giant cell carcinoma of the liver with ileal carcinoid, medullary breast cancer and pulmonary aspergillosis (case report), 373-376
And radiation exposure, 312-313
And vitamins, 282

Low-risk cancer populations, 352-361
(See also, Epidemiology)
Cancer incidence, 353-355, 358, 360
Mormons, 354-357, 359
Mortality rates of, 353-357, 359
Nonsmokers, 355-359
Seventh-Day Adventists, 354, 356-357, 359
In Sweden, 355-357, 359

Lung Cancer
Adenocarcinoma, 67, 235-237, 239, 272-273
Bronchioloalveolar cell carcinoma 235, 238, 242
Cancer spread by vein invasion, 136-137
Classification of, 67, 88-89, 233-234
Diagnosis of, 25-26, 237-239, 258-259, 263-273
Gallium scan in, 259, 263-273
(See also, GA-67 scan)
Tomography in, 263, 270, 273
In the elderly, 322, 327-328
Embryology of, 233-234
Epidermoid carcinoma, 67, 234-236, 272-273
Followup for, 244
Horner's syndrome, 261
Immunodeficiency in, 240

Incidence rates for, 233-235, 258
Large cell lung cancer (undifferentiated or anaplastic), 235-238, 272-273
Management of, 84, 88, 90-93, 242-244, 272-274, 327-328, 371-372
(See also, specific treatment modalities)
Metastases in, 85-88, 238-239, 266-270 273
Pancoast syndrome in, 238-240, 261-262, 274
Paraneoplastic syndromes in, 237
Pathogenesis of, 235
And radiation exposure, 311-313
Small cell anaplastic cancer, 84-86, 88-93, 234-237, 243-244, 274, 328
Staging of, 88, 240-242, 259-263, 266, 268-273
Survival rates for, 242-244, 258-259, 262, 266, 270, 274-275, 328
And vitamin A (retinoids), as preventive, 281
And vitamin K, role in carcinogenesis, 283

Lymphatic spread, of cancer
In cervical cancer, 132-134, 139-142
In lung cancer, 266-269
In melanoma, 204-207

Lymphomas
Hodgkin's disease
With cerebellar degeneration (case report), 246-249
Classification of, 72-73
Malignant lymphomas,
Classification of, 73-76
Diagnosis of, 74
Leukemias and lymphomas, distinction between, 74
Origin of, 75
Pseudolymphomas, 76
And radiation exposure, 312-313

M

Malnutrition, in childhood cancer, 40-41, 43

Mammography
Benefits of, 46-47, 49-50, 52
In Breast Cancer Detection Demonstration Projects (BCDDPs), 47-50, 63-64
Controversy concerning, 46, 49-51
Guidelines for, 46, 50, 52
In HIP studies, 45-50
Improvements in, 48-49
In mortality reduction, 50

Mastectomy, prophylactic, for Heredo-familial breast cancer, 221-222, 226

Mediastinoscopy, in lung cancer, 239-241, 266

Melanoma, malignant
(See, Skin cancer)

Metastatic cancer (See also, specific sites)
Direct invasion, 131
Examination of lymph nodes, 31
Implantation, tumor, 23, 28, 131-132, 138-139
Lymphatic spread, 132-134, 139-142
Vein invasion, 134, 136-137, 140, 142

Methotrexate
For breast cancer, 24
For small cell lung cancer, 274

Multiple Endocrine Adenomatosis (MEA), 220, 228-229
(See also, Genetics, and cancer)

N

National Cancer Institute (NCI),
Cooperative Clinical Trials Program, 286-290

Nevus
(See also, Skin cancer)
Classification of, 194-197
Management of, 197
Potential for malignant transformation, 194-197

Nitrogen mustard therapy (letter), 53

Nutritional therapy, for cancer
(See also, Enteral management, and Hyperalimentation)
In childhood cancer, 40-45
Parenteral management, candidates for, 78

O

Occupational cancer
(See also, Carcinogens)
And radiation exposure, 309-313

Ovarian cancer
Cause of death in, 341
Classification of, 68, 347-350
Cytogenetic factors in, 346
Detection of, 343-344, 346-347
Diagnosis of, 341, 344-347, 351
Of an adnexal mass, 351
And Heredo-familial breast cancer, 219, 222, 226
Incidence rates of, 342
Management of, 341-342, 346-347, 351
Of an adnexal mass, 351
Mortality rates of, 342-343, 346
Prevention of, 346-347
Staging of, 350-351
Survival rates for, 341

P

Pancreatic cancer
And radiation exposure, 312-313
Secondary to lung cancer, 263, 265-266
And tumor implantation during biopsy, 132
By vein invasion, 137

Pathology, general
(See also, Staging, and specific sites)

Of cellular aging, 344
Classification
Of cancer, 67-70
(See also, specific sites)
Of cervical cancer, 69-70, 181-186
Of lung cancer, 88-89, 233-234
Of lymphomas, 72-76
(See also, Lymphomas)
Hodgkin's disease, 72-73
Non-Hodgkin's disease, 73-76
Of ovarian cancer, 347-351
Of sarcomas, soft tissue, 70-73
Of functioning tumors, 130, 132-133, 135-137
Interaction between pathologist and therapist, 137-140, 142
Of lung cancer, small cell, 84-85, 88
Of lymph nodes, gross appearance vs microscopic examination, 132-134
Of melanoma, 66-67
Metastatic patterns, 131-141
(See also, Metastatic cancer)
Pathology report, 25, 32-33
Tumor radiosensitivity, assessment of, 138-139, 141
Tumor sterilization, in radiotherapy, assessment of, 139-140, 142

Phenylalanine mustard, in breast cancer management, 324

Pregnancy, and cancer
And cervical cancer, 178, 181, 188
And melanoma, 211

Proctosigmoidoscopy
In the detection of polyps, 223
In the diagnosis of ovarian cancer, 344
As a screening procedure for colon and rectum cancer, 126, 220, 223

Prostate cancer
Detection of, 116-118
In the elderly, 322, 325-326, 336
Incidence of occult tumors, 115-119, 325
Management of, 325-326
(See also, specific treatment modalities)
Pathologic grading of, 66

R

Radiation, low-level, 306-315
And cancer incidence, 311-313
And cancer risks, 307-313
And medical exposure, 310-313
And nuclear exposure, 306, 309, 312-313
And occupational exposure, 160-162, 309-313
And threshold levels of, 307-309, 312-313

Radiation therapy
For bone cancer, 138
For cervical cancer, 190
For childhood cancers, 41
In the elderly, 325, 328-329
In enteral nutritional management, 82
For lung cancer, 84, 88, 91, 93, 243-244, 273-274, 328
For melanoma, 138, 208-209
Pathologist, role in, 138-140, 142
For prostate cancer, 325
And radiation hazards, 311-313
And tumor radiosensitivity, 138-139, 141
And tumor sterilization, 139-140, 142

Radioimmunoassay
In ovarian cancer, 345
Pentagastrin radioimmunotherapy for Multiple endocrine adenomatosis (MEA), 229

Research, cancer
Of aging and cancer, 334-338
Data, classification of, 2-5
Of occupational carcinogens, 150-152, 156-163, 335-336
Of retinoids, 120-125

Retinoids (See, Vitamins)

Rice, Arnold Rich, biography of, 112-114

S

Sarcomas, soft tissue
Pathologic classification of, 70-73
Spread by vein invasion, 137

Skin cancer
Bowen's disease, 69-70
Classification of, 68-69
And immunotherapy, 209, 363
Melanoma, malignant
Amelanotic melanoma, 211-213
In blacks, 211
Classification of, 69
Diagnosis of, 198-199, 278
In the elderly, 323
Familial Atypical Multiple Mole-Melanoma syndrome (FAMMM), 222, 226, 228
(See also, Genetics, and cancer)
Immunotherapy in, 209
Incidence of, 276-279
Lentigo Maligna Melanoma (LMN), 197-198
Lymphatic spread in, 204-207
Lymph node dissection for, 202-207
Management of, 138, 201-209, 363
(See also, specific treatment modalities)
Mortality rates of, 278
Nevus, classification and treatment of, 194-197 (See also, Nevus)
Nodular Melanoma (NM), 196-198
Pathologic grading of, 66
And pregnancy, 211
Special sites, 209-210
Staging of, 196, 199-201
Superficial Spreading Melanoma (SSM), 196, 198
Survival rates for, 204-214, 278, 323
Unknown primary melanoma, 212
And radiation exposure, 311-313
And retinoids, 280-281
And ultra-violet light, 169-171
Vulva cancer, in the elderly, 322-323

Smoking, cigarette
Alcohol and, 101
Pharmacological effects of, 96-97
And population mortality rates, 355-360
Psychological effects of, 97-99
Horn's test, 97-99
Quitting, 98, 100-107
Obstacles to, 101-104
Physiological withdrawal, 100
Psychological withdrawal, 98, 100
And retinoids, 124-125, 284
Strategic withdrawal from, 98, 104-107
Teenagers and, 97
And vitamin C, 281

Sonography, in ovarian cancer, 345

Staging (See also, specific sites)
Of bladder cancer, 97
Of cervical cancer, 67
Of colon and rectum cancer, 67
Of lung cancer, 88, 240-242, 266, 268-270, 272-273
Sequential staging program, 271, 273,
TNM classification of, 240-241, 259-260, 262-263
Of melanomas, 196, 199-201
Clark-Breslow microstaging system, 196, 199-201
Clinical staging, 67, 199-201
Of tumors, general, 66-67

Statistics, cancer (See also, specific sites)
Incidence,
In children, 13
By sex and site, 6, 14
By stage, 21
By state, 16
Mortality
Age-adjusted, 10-12
Around the world, 18-19
In children, 13
By sex and site, 6, 8-9, 12, 15
By state, 17

Strong, Leonell C., biography of, 54-56

Surgery
For breast cancer, 323-324
For Cancer Family Syndrome (CFS), 226
For cervical cancer, 185, 188-190
For colon and rectum cancer, 328
In the elderly, 323-329
For Familial Polyposis Coli (FPC), 218, 224-225
For gastrointestinal cancer, 328
For hereditary colonic cancer, 226
For Heredo-familial breast cancer, 221-222, 226
For lung cancer, 91, 93, 242-244, 273-274, 327
For melanoma, 197, 201-208
Amputation, 206
Excision of primary tumor, 201-202
Lymph node dissection, 202-207
For ovarian cancer, 342, 346-347
Hysterectomy, 346-347
For prostate cancer, 325-326
For thyroid cancer, 323

T

Thermography, for breast cancer, 47

Thyroid cancer
In the elderly, 323, 336
And Multiple endocrine adenomatosis (MEA), 229
And radiation exposure, 311-313
And vein invasion, 136

Tomography
CT scan, in ovarian cancer, 345
In lung cancer, 263, 270, 273

Transitional cell carcinomas, cytologic diagnosis of, 27

U

Uterine cervical cancer
In the elderly, 322
As a result of radiation exposure, 312-313

V

Vitamins, and cancer
And interaction with chemotherapy, 280-286
Vitamin A (retinoids), 120-125, 280-281, 284
Vitamin B_6 (pyridoxine), 282
Vitamin B_{12}, 44-45, 281-282
Vitamin C, 44-45, 281-282
Vitamin E, 283
Vitamin K, 283

Author Index, 1979 Vol. 29, Nos. 1-6

A

Ackerman, L.V., 22-39, 66-77, 130-143
Albano, W.A., 216-232
Averette, H.E., 174-192

B

Barber, H.R.K., 341-351
Behar, J., 53
Benjamini, E., 362-370
Buell, D.N., 300-305
Butler, R.N., 333-340
Bybee, J.D., 127

C

Caradonna, R., 84-95
Carbone, P., 246-249
Carr, D.T., 233-245
Champion, L., 319-320
Christen, A.G., 96-107
Cooper, K.H., 96-107

D

Dailey, K. S., 300-305
DeMeester, T.R., 258-275
DiPalma, J.R., 280-286
Dugan, W.M., Jr., 300-305

E

Edney, J., 216-232
Enstrom, J.E., 352-361

F

Feinstein, A.R., 252-256
Findlay, G.M., 169-171
Fisher-Beckfield, P., 246-249
Fitzpatrick, T.B., 276-279
Fries, J.F., 316-318

G

Garfinkel, L., 2-5
Gastel, B., 333-340
Goldsmith, H.S., 194-215
Golomb, H.M., 258-275

H

Haas, J.F., 144-168
Hanlon, C.R., 173
Hill, N.O., 53
Hillinger, S.M., 84-95
Holleb, A.I., 63-64
Horton, J., 84-95
Horwitz, R.I., 252-256

J

Jacobs, E.M., 287-290
Jansen, M.A., 300-305
Jick, H., 250-251

K

Kennedy, B.J., 322-332
Khan, A., 319-321
Kissin, M., 126
Krakoff, I.H., 108-111

L

Lipkin, M., 291-299
Loftus, E.F., 316-318
Lohrman, R.G., 300-305
Lynch, H.T., 216-232
Lynch, J.F., 216-232
Lynch, P.M., 216-232

M

McMichael, R., 280-286
Minnick, D.J., 300-305
Morton, P., 126-128

N

Nelson, J.H., Jr., 174-192

O

Organ, C.H., 216-232

P

Paladine, W.J., 84-95
Peterson, B.A., 322-332

R

Rennick, D.M., 362-370
Rich, A.R., 115-119
Richart, R.M., 174-192
Rosai, J., 22-39, 66-77, 130-143
Rosenow, E.C., 233-245
Ruckdeschel, J.C., 84-95, 371-372

S

Schottenfeld, D., 144-168
Sherman, C.D., Jr., 371
Shils, M.E., 78-83
Shimkin, M.B., 53
Silverberg, E., 6-21
Silhaug, M., 319-320
Sinks, L.F., 319-320
Smits, H.L., 172-173
Sober, A.J., 276-279
Sporn, M.B., 120-125
Stolinsky, D.C., 373-376
Strax, P., 46-52
Strong, L.C., 57-62
Sun, N.C., 373-376

U

Upton, A.C., 306-315

V

Valtysson, G., 246-249
Van Eys, J., 40-45

W

Weiss, R.B., 287-290
Wood, J.R., 300-305